Loading
AZD4360 is an experimental antibody-drug conjugate from AstraZeneca in phase 2 trials for gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma, aimed at Claudin 18.2.
AZD4360 is an antibody-drug conjugate developed by AstraZeneca. Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). The sponsor states: AZD4360 is an antibody-drug conjugate targeting Claudin 18.2, being studied in advanced solid tumours including gastric, gastro-oesophageal junction, biliary tract and pancreatic cancers. ClinicalTrials.gov describes the intervention as: Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, biliary tract cancer and pancreatic ductal adenocarcinoma. The largest, NCT06921928, plans to enrol 31 participants (actual) with primary completion expected 2027-03-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
AZD4360 is an antibody-drug conjugate targeting Claudin 18.2, being studied in advanced solid tumours including gastric, gastro-oesophageal junction, biliary tract and pancreatic cancers. Connects to Claudin 18.2.
1.AZD4360's antibody arm binds Claudin 18.2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD4360" OR ABSTRACT:"AZD4360") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD4360, not a curated reading list.
Shares Claudin 18.2, AstraZeneca, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Claudin 18.2, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Claudin 18.2, Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma), Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Claudin 18.2, Gastric & gastro-oesophageal junction cancer and the tag pipeline.